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The development of safe and effective pediatric drugs continues to fall short.1 The paucity 
of new therapies is particularly stark for rare diseases, which disproportionately affect 
children and collectively affect an estimated 25 million people in the United States and 30 
million in Europe.2 Since the 1980s, US policymakers have enacted a range of policies to 
stimulate drug development for rare diseases, defined as those affecting fewer than 200 000 
individuals in the United States. The most notable policy is the 1983 Orphan Drug Act, 
which grants 7 years of marketing exclusivity as well as subsidies and tax credits to 
pharmaceutical companies bringing a drug for a rare disease to market. While the Orphan 
Drug Act has been credited with stimulating product development for rare diseases, only 
one-quarter of orphan drugs were approved explicitly for pediatric indications between 2000 
and 2009.3
To incentivize the development of novel therapeutics for children, US Congress established 
the Rare Pediatric Disease Priority Review Voucher (PRV) program, passed as part of the 
Food and Drug Administration (FDA) Safety and Innovation Act. To qualify for the 
program, the new drug or biologic must be indicated to treat a rare pediatric disease, 
defined as a disease that either affects fewer than 200 000 individuals primarily aged 0 to 18 
years in the United States or affects more than 200 000 individuals aged 0 to 18 years of age 
but for which there is no reasonable expectation that the cost of developing and making the 
drug available will be recovered from sales in the United States. Once approved, the sponsor 
of the drug is issued a voucher that can be freely transferred or sold and entitles the holder to 
a priority FDA review of any new drug or biologic application, with the expedited review 
accelerating market entry by up to 6 months.
There are a number of important differences between the pediatric PRV program and the 
Orphan Drug Act, with more stringent requirements applying to the PRV program (Table).4 
For example, to gain pediatric PRV approval, the rare pediatric disease product cannot 
contain an active ingredient (or an ester or salt of the active ingredient) of a previously 
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approved agent. In addition, the FDA can revoke the pediatric PRV if the product for which 
the voucher was awarded is not marketed within a year of approval. The program is also 
subject to a sunset provision, which will be effective 1 year after the first 3 vouchers are 
granted unless the program is reauthorized by Congress.
Owing to its novelty and limited track record, there are important unanswered questions 
about the pediatric PRV program. As the FDA develops final guidance for the industry and 
as policymakers and clinicians review emerging evidence from drugs approved through this 
new pathway, it is critical to consider the impact of the program in light of several key 
factors. First, manufacturers can qualify for the pediatric PRV even if their product is 
intended to treat a nonrare condition, as long as there is no reasonable a priori expectation of 
recouping costs. However, the statute is silent on whether the FDA can withdraw a pediatric 
PRV if the patient population is later found to be larger than the threshold. A claw-back 
provision has precedent in pharmaceutical regulation and could ensure that products 
receiving PRV designation are truly intended to treat unmet medical needs. For example, in 
the Humanitarian Device Exemption Program—the device analogue to the orphan drug 
program—the FDA withdrew marketing authorization in 2006 for 2 devices treating a 
condition later determined to be significantly larger than the statutory limit for a rare 
disease.5
Second, the accessibility of these new therapeutics to patients remains a source of 
controversy. On February 14, 2014, the FDA approved the first drug through the pediatric 
PRV program, elosulfase alfa (Vimizim; BioMarin Pharmaceutical), an enzyme replacement 
therapy for the treatment of mucopolysaccaridosis IV, or Morquio A syndrome, which 
affects approximately 800 individuals in the United States and has no existing treatment 
options. The company subsequently announced that the annual net cost of therapy is 
expected to be $380 000 per patient after spending approximately $300 million on the 
development program.6 Based on equity research analyst estimates, gross revenues from the 
drug are projected to surpass this investment within just 3 years, raising questions about 
whether participation in the program should be contingent on certain limitations to the costs 
passed on to patients. Companies should ensure that access programs reach patients who 
cannot afford treatment, either because of insufficient or lack of insurance coverage.
Finally, policymakers should revisit the program as the sunset provision approaches with a 
view toward continuing programs that maximize innovation, benefit vulnerable populations, 
and minimize costs to taxpayers and public payers. There may be valuable lessons from 
other pharmaceutical incentive programs for the PRV program. For example, in 2007, a 
similar voucher program was established to award priority review vouchers for 
manufacturers developing drugs for neglected tropical diseases. Although there were some 
initial concerns that the tropical disease PRV would be misused to bring inadequately 
reviewed drugs more quickly to market,7 only 1 drug has been submitted for approval 
through this pathway, by Novartis for canakinumab in 2011, which did not ultimately lead to 
the drug’s approval. As the pediatric PRV program attracts greater attention, it will be 
important to test whether and how the PRV influences the research and development 
priorities of companies and the approval of other drugs.
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The creation of the pediatric PRV program and the recent approval of the first drug via this 
mechanism mark a new chapter in regulatory efforts to address and correct the significant 
unmet medical needs of diseases affecting children. Close monitoring of the program’s 
implementation and impact should serve to guide refinements in future renewals and ensure 
that the program meets its intended purpose of rewarding innovation and increased 
availability of safe and effective therapies for underserved populations and conditions.
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